NASDAQ:XGN Exagen (XGN) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free XGN Stock Alerts $1.40 +0.02 (+1.45%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$1.36▼$1.4150-Day Range$1.37▼$2.2552-Week Range$1.30▼$3.92Volume17,178 shsAverage Volume23,700 shsMarket Capitalization$24.14 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Exagen alerts: Email Address Exagen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside328.6% Upside$6.00 Price TargetShort InterestHealthy0.15% of Float Sold ShortDividend StrengthN/ASustainability-1.29Upright™ Environmental ScoreNews Sentiment1.10Based on 2 Articles This WeekInsider TradingSelling Shares$24,417 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.46) to ($1.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.84 out of 5 starsMedical Sector91st out of 908 stocksMedical Laboratories Industry3rd out of 20 stocks 3.5 Analyst's Opinion Consensus RatingExagen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageExagen has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.15% of the float of Exagen has been sold short.Short Interest Ratio / Days to CoverExagen has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exagen has recently decreased by 41.95%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldExagen does not currently pay a dividend.Dividend GrowthExagen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExagen has received a 70.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" and "Immunology laboratory services for research" products. See details.Environmental SustainabilityThe Environmental Impact score for Exagen is -1.29. Previous Next 3.4 News and Social Media Coverage News SentimentExagen has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Exagen this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Exagen to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exagen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,417.00 in company stock.Percentage Held by Insiders36.80% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.25% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exagen are expected to grow in the coming year, from ($1.46) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exagen is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exagen is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExagen has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Exagen Stock (NASDAQ:XGN)Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.Read More XGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XGN Stock News HeadlinesApril 26, 2024 | americanbankingnews.comExagen Inc. (NASDAQ:XGN) Sees Large Decline in Short InterestApril 16, 2024 | morningstar.comExagen Inc Ordinary SharesApril 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.March 21, 2024 | finance.yahoo.comAnalyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Annual ReportMarch 20, 2024 | seekingalpha.comExagen Inc. (XGN) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Exagen on Strong Financials and Strategic Growth InitiativesMarch 20, 2024 | finance.yahoo.comExagen Full Year 2023 Earnings: Beats ExpectationsMarch 19, 2024 | finance.yahoo.comExagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call TranscriptApril 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.March 19, 2024 | markets.businessinsider.comExagen’s Strong Q4 Performance and Positive Outlook Justify Buy RatingMarch 18, 2024 | markets.businessinsider.comHere's what to expect from Exagen's earningsMarch 18, 2024 | msn.comExagen reports Q4 resultsMarch 18, 2024 | investorplace.comXGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q4 2023March 18, 2024 | msn.comAnticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See UpticksMarch 18, 2024 | globenewswire.comExagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 ResultsMarch 18, 2024 | finance.yahoo.comXGN Apr 2024 2.500 putMarch 8, 2024 | finance.yahoo.comExagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor ForumMarch 8, 2024 | globenewswire.comExagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor ForumMarch 7, 2024 | globenewswire.comExagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024February 6, 2024 | finance.yahoo.comDespite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain StockJanuary 30, 2024 | finance.yahoo.comExagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceJanuary 8, 2024 | msn.comExagen reaffirms FY23 revenue of at least $50MJanuary 7, 2024 | finance.yahoo.comExagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms GuidanceDecember 30, 2023 | benzinga.comExagen Stock (NASDAQ:XGN) Dividends: History, Yield and DatesDecember 20, 2023 | msn.comExagen submits plans for new solar farm in WiltshireNovember 17, 2023 | msn.comExagen files for a $150M mixed shelf offeringNovember 14, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Exagen (XGN) and Milestone Pharmaceuticals (MIST)See More Headlines Receive XGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:XGN CUSIPN/A CIK1274737 Webwww.exagen.com Phone760-560-1501FaxN/AEmployees174Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+328.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,690,000.00 Net Margins-45.08% Pretax Margin-45.02% Return on Equity-80.28% Return on Assets-36.27% Debt Debt-to-Equity Ratio0.85 Current Ratio4.02 Quick Ratio4.02 Sales & Book Value Annual Sales$52.55 million Price / Sales0.46 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book1.05Miscellaneous Outstanding Shares17,240,000Free Float10,893,000Market Cap$24.14 million OptionableOptionable Beta1.19 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Tina S. Nova Ph.D. (Age 70)Executive Chairman of the Board of Directors Comp: $65kMr. John Aballi (Age 39)CEO, President & Director Comp: $558.84kMr. Kamal Adawi M.S. (Age 45)MBA, CFO & Corporate Secretary Comp: $483.28kRyan DouglasInvestors Relations OfficerMr. John Wegener (Age 55)Senior Vice President of Sales and Marketing Dr. Andrew L. Concoff FACRM.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory BoardDr. Michael I. Nerenberg M.D. (Age 69)Chief Medical Officer More ExecutivesKey CompetitorsDermTechNASDAQ:DMTKPsychemedicsNASDAQ:PMDAkuminNASDAQ:AKUMQCentogeneNASDAQ:CNTGBioNexus Gene LabNASDAQ:BGLCView All CompetitorsInsiders & InstitutionsWasatch Advisors LPSold 63,413 shares on 4/18/2024Ownership: 4.564%Kamal AdawiSold 12,784 sharesTotal: $24,417.44 ($1.91/share)RTW Investments LPBought 12,170 shares on 2/14/2024Ownership: 8.825%Wasatch Advisors LPSold 5,965 shares on 2/14/2024Ownership: 4.987%Stonepine Capital Management LLCSold 533,807 shares on 2/13/2024Ownership: 3.928%View All Insider TransactionsView All Institutional Transactions XGN Stock Analysis - Frequently Asked Questions Should I buy or sell Exagen stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XGN shares. View XGN analyst ratings or view top-rated stocks. What is Exagen's stock price target for 2024? 2 analysts have issued twelve-month price targets for Exagen's stock. Their XGN share price targets range from $6.00 to $6.00. On average, they anticipate the company's share price to reach $6.00 in the next year. This suggests a possible upside of 328.6% from the stock's current price. View analysts price targets for XGN or view top-rated stocks among Wall Street analysts. How have XGN shares performed in 2024? Exagen's stock was trading at $1.99 at the beginning of the year. Since then, XGN stock has decreased by 29.6% and is now trading at $1.40. View the best growth stocks for 2024 here. Are investors shorting Exagen? Exagen saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 11,900 shares, a decrease of 42.0% from the March 31st total of 20,500 shares. Based on an average trading volume of 38,200 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.2% of the company's stock are short sold. View Exagen's Short Interest. When is Exagen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our XGN earnings forecast. How were Exagen's earnings last quarter? Exagen Inc. (NASDAQ:XGN) posted its earnings results on Monday, March, 18th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.02. The business earned $13.77 million during the quarter, compared to the consensus estimate of $11.43 million. Exagen had a negative trailing twelve-month return on equity of 80.28% and a negative net margin of 45.08%. During the same period in the prior year, the firm posted ($0.58) EPS. What guidance has Exagen issued on next quarter's earnings? Exagen issued an update on its FY 2024 earnings guidance on Monday, March, 18th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $54.0 million-$54.0 million, compared to the consensus revenue estimate of $54.1 million. What is Ron Rocca's approval rating as Exagen's CEO? 5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees. When did Exagen IPO? Exagen (XGN) raised $50 million in an initial public offering (IPO) on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO. Who are Exagen's major shareholders? Exagen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wasatch Advisors LP (4.56%). Insiders that own company stock include James L L Tullis, John Aballi, Kamal Adawi, Mark Hazeltine and Wendy S Johnson. View institutional ownership trends. How do I buy shares of Exagen? Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XGN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
